# NCT06385925 (NCT06385925)

> A Study of TSN1611 Treating Patients With Advanced Solid Tumors Harboring KRAS G12D Mutation

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT06385925
- Phase: PHASE1, PHASE2
- Status: RECRUITING
- Sponsor: Tyligand Pharmaceuticals (Suzhou) Limited
- Conditions: Malignant Neoplasm
- Interventions: TSN1611; TSN1611; TSN1611; TSN1611
- Enrollment: 440
- Primary outcome: Dose limiting toxicities (DLTs) in phase 1 part
- Primary outcome: Objective response rate (ORR) in phase 2 part

## Commentary we found

- X threads: 4

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=nct06385925